FINHUB Insights

IDXX · Q1 FY26 · Mar 31, 2026

Idexx Laboratories Q1 FY26: where the revenue came from and where it went

Idexx Laboratories Q1 FY26: revenue $1.1B (+14% year over year). Net profit $0.3B. Largest cohort IDEXX VetLab consumables $0.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 5, 2026 10-Q
Sankey diagram of Idexx Laboratories's income statement for Q1 FY26: revenue of $1.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.1B +14% year over year
Gross profit$0.7B 63% margin
Operating profit$0.4B 32% margin
Net profit$0.3B 24% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 1.1 100% +14%
IDEXX VetLab consumables 0.4 36% +20%
Reference laboratory diagnostic… 0.4 36% +12%
Rapid assay products 0.1 9% +1%
Recurring revenue 0.1 9% +12%
Water segment revenue 0.1 9% +11%
Cost of revenue−0.436%
Gross profit0.763% margin+1pp
Research & development−0.16%+0pp
Sales & marketing−0.215%+0pp
G&A−0.110%+1pp
Operating profit0.432% margin+0pp
Tax−0.1
Net profit0.324%+0pp
Filing on EDGAR More quarters of IDXX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters